-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 SEpG+HKe+dbJITeBGG11zXll5bdQPeQYmUrCIYHYP6tCvXzXThVyyq2j5yL0jN2L
 V3+Z8XdNFSuZC1FqHeHI+A==

<SEC-DOCUMENT>0001193125-11-019714.txt : 20110201
<SEC-HEADER>0001193125-11-019714.hdr.sgml : 20110201
<ACCEPTANCE-DATETIME>20110201084214
ACCESSION NUMBER:		0001193125-11-019714
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20110128
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20110201
DATE AS OF CHANGE:		20110201

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RESMED INC
		CENTRAL INDEX KEY:			0000943819
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				980152841
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15317
		FILM NUMBER:		11561489

	BUSINESS ADDRESS:	
		STREET 1:		9001 SPECTRUM CENTER BLVD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92123
		BUSINESS PHONE:		8587462400

	MAIL ADDRESS:	
		STREET 1:		9001 SPECTRUM CENTER BLVD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92123
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act of
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): January&nbsp;28, 2011 </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>ResMed Inc. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>001-15317</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>98-0152841</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>9001 Spectrum Center Blvd.
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>San Diego, California 92123 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive offices) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registrant&#146;s telephone
number, including area code: (858)&nbsp;836-5000 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>N/A </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Former Name or Former Address, if Changed Since Last Report) </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see</I> General Instruction
A.2. below): </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;5.02.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers.
</B></FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <I>Resignation of Chief Executive Officer. </I>On January&nbsp;28, 2011, Kieran Gallahue announced his
decision to resign from his position as Chief Executive Officer, President, and a director of ResMed Inc., which the board accepted, effective as of January&nbsp;28, 2011. Mr.&nbsp;Gallahue will remain an employee until February&nbsp;1, 2011.
Mr.&nbsp;Gallahue&#146;s resignation from our board of directors did not result from any disagreement with us over our strategy, operations, policies, or practices. Mr.&nbsp;Gallahue will not receive any severance benefits from us, nor will any of
his unvested and outstanding equity awards vest in connection with his resignation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">After Mr.&nbsp;Gallahue&#146;s
resignation from our board of directors, the board reduced the authorized number of directors from eight to seven directors, also effective January&nbsp;28, 2011. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(c) <I>Appointment of Dr.&nbsp;Farrell as Interim Chief Executive Officer. </I>In connection with Mr.&nbsp;Gallahue&#146;s resignation, the board appointed Dr.&nbsp;Peter Farrell, our current Executive
Chairman, to the additional position of our interim Chief Executive Officer and President, effective January&nbsp;31, 2011. For the duration of Dr.&nbsp;Farrell&#146;s assumption of the additional responsibilities of interim Chief Executive Officer
and President, he will receive an annual base salary of $820,050, which represents the annual base salary we paid to Mr.&nbsp;Gallahue before his resignation, and represents an increase of $323,925 from Dr.&nbsp;Farrell&#146;s current salary. We
intend to conduct a search for a new chief executive officer. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Farrell is our founder and has been Chairman and a
director since our inception in June 1989. He served as Chief Executive Officer from July 1990 until December 2007; from January 2008 Dr.&nbsp;Farrell has been ResMed&#146;s Executive Chairman. From our formation in 1989 until September 2004,
Dr.&nbsp;Farrell was also our President. He also currently serves as Chairman of the Executive Council of the Division of Sleep Medicine at Harvard Medical School and on faculty advisory boards at the University of California San Diego.
Dr.&nbsp;Farrell is also a director of NuVasive, Inc., a NASDAQ-listed company, which develops and markets products for the surgical treatment of spine disorders, and is the non-executive chair of QRxPharma, a clinical-stage specialty pharmaceutical
company listed on the Australian Stock Exchange. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Farrell&#146;s son, Michael Farrell, is our Sr. Vice President,
Strategic Business Unit &#150; Sleep and became an executive officer on March&nbsp;1, 2010. In Dr.&nbsp;Peter Farrell&#146;s new role as interim Chief Executive Officer and President, Michael Farrell will report to Dr.&nbsp;Farrell. For more
information on related parties, please refer to the &#147;Certain Relationships and Transactions with Related Persons&#148; section of our Proxy Statement filed on September&nbsp;30, 2010. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On February&nbsp;1, 2011, we publicly announced Mr.&nbsp;Gallahue&#146;s resignation and the board&#146;s appointment of Dr.&nbsp;Farrell
as interim Chief Executive Officer and President in the press release attached as Exhibit 99.1 and incorporated here by reference. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Statements and Exhibits. </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>(d) Exhibits </I></B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;Exhibits&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description of Document</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release, dated February&nbsp;1, 2011</FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have authorized the person whose signature appears below to sign this report on our behalf, in accordance with the Securities Exchange Act of 1934. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0">

<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">ResMed Inc.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: February 1, 2011</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/<SMALL>S</SMALL>/&nbsp;&nbsp;&nbsp;&nbsp;D<SMALL>AVID</SMALL>
P<SMALL>ENDARVIS</SMALL></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">David Pendarvis</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Its:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Secretary, Global General Counsel and</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President &#150; Organizational Development</FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit Index </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;Exhibits&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description of Document</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release, dated February&nbsp;1, 2011</FONT></TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px">

<IMG SRC="g145714g24t95.jpg" ALT="LOGO"> </P>
 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>RESMED INC. ANNOUNCES MANAGEMENT CHANGES </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">SAN DIEGO, California, February&nbsp;1, 2011 &#150; ResMed Inc. (NYSE: RMD) today announced changes to its management team. Kieran T. Gallahue has resigned his position as Chief Executive Officer and
President, and as a director, effective January&nbsp;28, 2011. The board has appointed Dr.&nbsp;Peter&nbsp;C. Farrell, ResMed&#146;s founder and executive chairman, to serve as interim Chief Executive Officer and President, effective
January&nbsp;28, 2011. Dr.&nbsp;Farrell will also continue to serve as executive chairman of the board of directors. ResMed does not anticipate any material change in strategy or operations as a result of this management change. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Farrell founded ResMed in June 1989, and has been chairman since that time. He served as Chief Executive Officer from July 1990 until December
2007; from January 2008 Dr.&nbsp;Farrell has been ResMed&#146;s Executive Chairman. He also currently serves as Chairman of the Executive Council of the Division of Sleep Medicine at Harvard Medical School and on faculty advisory boards at the
University of California San Diego. Dr.&nbsp;Farrell is also a director of NuVasive, Inc., a NASDAQ-listed company, which develops and markets products for the surgical treatment of spine disorders, and is the non-executive chair of QRxPharma, a
clinical-stage specialty pharmaceutical company listed on the Australian Stock Exchange. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Gallahue will continue as an employee until
February&nbsp;1, 2011. He leaves to become chairman and chief executive officer of another medical technology company. Mr.&nbsp;Gallahue will not receive any severance benefits in connection with his departure. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Farrell commented, &#147;Kieran&#146;s resignation came as a surprise but we wish him well. During his three years as Chief Executive Officer,
he helped build a strong senior management team and I look forward to leading that team as long as is needed. As executive chairman, I remained closely involved with ResMed&#146;s strategy, so stepping back into the CEO role will not be a novelty
for me and will ensure continuity for the team. The market for sleep-disordered breathing continues to bring forward enormous opportunities, and I am as excited as I have ever been about ResMed&#146;s future.&#148; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Gary Pace, ResMed&#146;s lead director commented, &#147;The Board thanks Mr.&nbsp;Gallahue for his contributions during his time with the
company, and we wish him well. The board&#146;s succession plan calls for Dr.&nbsp;Farrell to step into the role again as Chief Executive Officer and President for as long as needed; this will take immediate effect. Dr.&nbsp;Farrell thoroughly
understands ResMed&#146;s markets and technology and is passionate about ResMed and its people. The board has complete confidence in Dr.&nbsp;Farrell, and the senior management team. We expect a smooth transition. The ResMed board will shortly begin
a search for a replacement.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About ResMed </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">ResMed is a leading developer, manufacturer and distributor of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders. The company is dedicated
to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals of the potentially serious health consequences of untreated sleep-disordered
breathing. For more information on ResMed, visit <U>www.resmed.com</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Further information can be obtained by contacting Constance Bienfait
at ResMed Inc., San Diego, at (858)&nbsp;836-5971; Brett Sandercock at ResMed Limited, Sydney, on (+612)&nbsp;8884-2090; or by visiting the Company&#146;s multilingual Web site at www.resmed.com. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Statements contained in this release that are not historical facts are &#147;forward-looking&#148; statements as contemplated by the Private Securities
Litigation Reform Act of 1995. These forward-looking statements, including statements regarding the Company&#146;s future revenue, earnings or expenses, new product development and new markets for the Company&#146;s products, are subject to risks
and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Those risks and uncertainties are discussed in the Company&#146;s Annual Report on Form 10-K for its most
recent fiscal year and in other reports the Company files with the U.S. Securities&nbsp;&amp; Exchange Commission. Those reports are available on the Company&#146;s Web site. </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g145714g24t95.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g145714g24t95.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`)@"Z`P$1``(1`0,1`?_$`,8``0`"`P`#````````
M``````H)"P`'"`,$!@$!``(#`0`#````````````"``'!08)!`$"`Q````8"
M`0($`P,%#`L!`````0(#!`4&!P@1``DA$A,*,4$4(C(544(C%AAA,V,T-575
M%Y?76)BQ4F*"DB36)S<X61H1``(!`P,"`@8%!0H+"0````$"`Q$$!0`2!B$'
M,1-!46%Q(@B!D3(4%J%"(Y34P5)B<H+2DQ555M&2HC-3@],D5'08\',T1&0U
M128G_]H`#`,!``(1`Q$`/P!_'4U-5B^]_<#V9OVZNT%AQUL7FRN45WG&^0]&
MKU4R;<(B#95BMSJ]4KR43%1,LW8MTWD?#I+<))AZBBHF\3&'GI9P7@7&[#AN
M,M\AC[.2]%E$TC/#&S%W4.^YF4DT9B.IZ`4T$.:<XY'<\LOCC[Z[CM!<NJ*D
MLBKM5BJT56H*J`>@UZ(,>\Z8"F+%=R82F*!BB$3L<("4P`)1`0:^("`]?IYG
M9X=-_'?\:T_PZ_*O=KU9[ZKO_!K7]TSMW2<`.8B6R1E'>/#J\@N8D'(7^P9H
MI:4BX0+ZYT(Y>SJL6K]9(A?,9,@G$"AR(<=>^SPG;+/*\..ML+=JH^(1);R4
M!Z5.P$CWFFO%>9ON1A=L^1N,M;@GX3*]P@)'7IO(KI&_8<[S6?LZ9R8:;;8V
MP<GO+C7IZ2P]E*49,&=S1GJI&.;!*TVWO8Y!BUL;.2KK)TX9/E4OKTW#44E5
M%RK$%$[]\^SN!P>$;E_%8ONR0R*+B%23&5<A!(@))0ARH90=I#5`4J=UW]H>
MZ66SF3'&N1.)II$8PRD`/N4%BC$4W`H&(8_$"M"6W?"O_HD:26LZFIK.IJ:S
MJ:FLZFIK.IJ:SJ:FJS#N'=P/9.^;T[33.,-BLT5Z@AFFVU:C0-/R5<(6`0KU
M,?%I,2:(B(F609($DTX$'(@D0/457,8>3&'KI-V^X%QVPX1C(<EC[.2^^YQO
M(TD,;-OD'F-N9E)-"U.IZ`4]&@KSGG'(KGF%\,9>W<=H+ED1(Y9%6B'8I558
M#X@H/0=2:^G4B_MT-D]A<F]PZ0J.3\VY8R%7%->\G/AK]YR!:K+$H2D?8L??
M32"<9,RCMH20;$553*IY/.0BAP`0Y'JO/F&X[@,;P!;K&V5K;W'W^$;XXD1J
M%):BJJ#0]#2OH&MU[(\BSV2Y?):Y.[N9X?NDGPR2.X!#(:T9B*BE/<3IU,K*
M1L'&2,U,/FL9$0[!Y*2LD^73;,H^-CVZCM\^>.%3%2;M6C9$RBAS"!2$*(B/
M`=""**2>58(5+3.P50!4DDT``]))Z`:6;ND:&20A8U!))Z``=22?4!JLMWK[
MHFS&QVUV;LLXPSKF.B8H>6U>%QI6J9?+55H&*QY7CF@:B\5C(619,49.R,V7
MXBZ.8OJ*.G9P$1`H`'2;@W;/C?'>+66*R5C9SY18@TSR1([-*_Q2#<P)(4G8
MOH"J-!/F7<3D68Y%=WV+O+N'&"3;&L<CHH1?A4D*0`6`W-7KN)ZZE4]M[>ME
MM@]VKS9LE9VS+>\?X<PI.RSN"MV1K?8J\ZMMVFHBL5I-Y%RDJZ8+KI1))=PB
M)R")#H`8O!@`>JN^8JRXY@.%PVV.L;."_O+Q5#1PQHP2-6=Z,J@CXO+!H?`T
MU8?8W(<ASG(Y[C)7EU/8V]L3M>61UWN0JU#,1]DN>OI7IIQO0FTJ]9U-36=3
M4UG4U-9U-36=34UG4U-<Y[?9=1P'JML5FA5R#53&6%\CW"/5$>!&:AZK)N()
M`@\A^D=S16Z1/GYCAUL7$<2<[RG'8<"HN;R&,_Q6<;C]"U.L/R'(_P!48&\R
M?YT%K(X_C*A*CWEJ`:K%>WWB)UL-O)JIBIX@O*IW3.M#<VH!(=RHO7(.<1N%
MW=N0\3')^KL*\45,;PXY$>NE7/<LO'^$93**0IAL9=GHH[*4C`_ELH&@5PC'
M-G.:6-G]I9+M2U>I**VY_P#(#'Z*ZM=NN6>NANCU>Y$V!PO1]`;5@^TR5;E\
MNYCM%#1QK3E%FKRR1`5BVQ-FG<@D8E$[N(CHF$C%V17A@3*JM(%;E$P*'`+_
M`/EUP&9O>>19NU61,3:12^=)U"-O1D6*O@Q+$-MZT";C2@U3?>[,XNRX9+C+
MEHVR%T\8B0]6&UU9GH.H`4%=WA5@/`G1VO;@ZUVS,'<'K^96T>Z)C[6BL6:V
MVB=%-0K$UHN-;F:32ZRFY`OIFDWYIAW(>ESS]+&J"/')>4'\Q')+3$<!DP[,
M/O\`DI$C1?3LC=9)'IZAM5:_OG&J2[%8"YR'+US&TBSL4=BWH+.C1JOO.YF'
ML1M2I>X4[G6T>J>QV&<+ZO9KE<5$;8@>7[(Y82'J<JI)R%IM+^*K2#\]E@)L
M[?\`#(RJ.%2%1%,#%><F\WV>*N[`]M>,\HX[>9GDUDEU6[$46YG&T(@9Z;'6
MNXN`:U^STU8O>;GW(.-YBTQ7'KEH)#!OD`5&W%W*J#O5J$;#2E/M=?1K@N$R
M[[GBR0L/8H)#:23A)^+CYN&DF^-,.>A(14JT1?QSY$%:NFJ"3MFX(H4#%*8`
M-X@`\AUO<^*^6JVF>WG_`*K6>-BK`S3U#*:$'])Z"*:U6'(=_IXEGB-T8G4,
M#Y4'4$5!_P`WZCKZB#N?NA9><A(EX3:&'9RLQ%QCN7>XWPRDSB6L@_;M',H\
M5_5D?3:QZ"QEE#<#Y2$$>O+/:?+/%"\J#%NRH2%$T]6(!-!^D\3X#VZ]5O/W
M_EG2.1KE$9@"3%!0>T_H](G[L_=)A>V+A.F,XF-9Y/V*R6T=1>-J[/+F;Q";
M>O-62%BR3>RQAVKS\$8NG:)$VC84%)!ZOZ2:B2::RJ1\[5=L9NY6:F>5C;<>
MMF#3,O5JN24ABK4;B`:L:A%%2"2H-Q]Q>?P<"Q4;*HGR\]1$K>'PTW2/2AH*
MCH*%B:`@!B#;4I'W(O<#K2.=Z'>LTU['EG(,G4U(/(M*UMJDS&&,86SBG5I&
M6J<O+PAR^#=\N1=-T3[17"OWND7>'Y=N`W)P=]#929"+X9-T4EVZMZ1(Y60*
MWK4$%?#:/#5)6A[X\Q@&8LY;B&RDZIMD2W4J?#:NZ,LOJ8@U'YQUIK%O=C[J
M7;5V5)C/;FV9+O\`%5B6AT\J87SL_;6V67J4D*+A2;HM].J_DVSM6)4,YBWC
M21=13DY0*JFJ7S`7+Y3M7VO[C\<.2XI%;02R(WDW%L/+4.*C;)$``1NZ.K('
M'H(.L3C^X_<+@^?&-Y2TTT:L!)%,=[%33JDA)-:?9*N4KXAAIUN=<\U['>IV
M5=DXR12/7:Q@>UY;@)%3]$1XU;T=Y9JX8H&\2J2*@MRD+\?,H`="#!X*XR'*
M[7CDJ_[Q+?)`X]1,H1_JZ_5I9Y7+0V.`N,VC`P16CS*?00(RZ_7T^O59YVW,
M/*[*[[:U8ZFDU9)K8\I(7&X"<OK"XA:2SE,DVA1UY@,4R3II7%2J";P'U.!^
M/72+N)EQQS@N1R,-%>.V*)[&D*Q)3W,XI[M!3@&,&?YS96DQ+(UR'8^M8ZR-
M7WJAKJ1[VX[LI.ZNU`Q!Y?XDSHB4"<`1,WK0KP>0\/T8%;"4`#YB'RZKOYAT
MKVO/\&ZMOW1^[K>^QY__`$"7VV\O[FD=>XFW.-K/I`^Q%590&>3]K'K_`!C'
M`@N9-_%XS:M$G>5IY/TSE4(1S$NFT(`B'WID3%\4QZ._R^<._$G-!EKI:XW%
M@3&HZ&8FD"_00TG^KIZ=77WHY3^'^)M8P-2_OR8E]8CI^E;W$%8S_P!Y4>&A
M89JPXG@72C5E>>CB-,D;96.\;!NBK$\DA%X1I"+?'&&FAR#]M-O;9F4LTT'@
M`*MS-#?$@<,K#9@YWF636!JX[%1QVHIX-<25EN#[XU$,?L._UZ+N9Q8P?#+`
M3*/O^2E>X8^D0I\$'^.3,U?2I3TZ51[5G#QZ[K+L5G!XS!)?*688JDQ+HZ?"
MB\%BRLIKJ*('$`$6QY^]/$QX^R*C<0^)1X+OS0Y<7'),?A$:JVUHTC#U-,].
MOMVQ*?<=(#Y?,6;;CMWE'6CW%P$!]:Q+4'W;I&'T:B%S)W:NZ?G;>/,F)]-<
MUY(DH:=S-DJOX2Q32JCC>7>J5*G/9DC-.-4EJFZ=N2%KU=6D%E5W)N"><PFX
M``ZMK#]J>V&#X39Y7E]E;+-'9PM<SR/*H\R0+7=20`?&X4`#U:KO*]Q^X>6Y
MC<XCBMS(8VN)%AC2.)JHA8@@M&3]A=QJ?7K:7]8?NC?YKVJ_LTPS_P!-=8S[
MA\LO[[%?TT_^TUDOO?S!?^J_HH/]GJ2OM.2O?'MNX$+^W<_SG`Z\P%#N\W,-
M+_3L:0,%9K09HSA:K!_6UV":RXND7DN>0*1-0@&!B/G$2\E&N.ZD?92UXD_X
M'6Q?/R3QJIBDE9D2I9VHSE:479U'YW3KK>NWC]V)^0#\8M.N'6)R0R1*&:FU
M5JJ*U:MN%#^;U]O*'?*[K&Y&#-]5L`:IYSGL<5NC8WQ[&6*`K<%39DTQD>XF
M?V8ZBRMAKDV[!]^`3D2W(DF<A`X^[YA$1VGLEVNXAF^"C/<IL8[BYGN)61W:
M1=L*40`;'44WJYJ1]--:QW9[B\HPW+1A>-W1BCC@C#*J1N3(U7_.1C]AD``]
M7MUHU>[^Z2;H*N%([:`R:*1ECE0H6#'2XD(43B"35M!*N5U1`/!,A#',/@`"
M/AUFUL_ED9@H.,J33K+<`?67H/?X:QINOF#`+'[S0#_16Y_((ZZ]+2OW"VZ>
M#L\PN,M[GRF2<8'MB5+R2:TT.)HV7\2N5)`L8^G`""B:V#\U8=&]21C)-D==
M1NF<J*J2H%\WWYEV!X;F\&^2X.HMLEY7F0[)6D@G%*A?B9Z;QT1T8`$@D,-?
MAQ7O1R?%YE<9S/\`2VGF;)"T:QRQ&M*T54^SUW*REC2@(.G<_C,3_.;#^3?Q
MG^-H?R3_`#G]_P#B'\+]S]WH.^1-^];[6WP_._>^_P!FEMO3]\/"OB/#U^[V
M^&H*O<>9E4Q=VS[I4V;PC:3SID;'F*DDP,`+K1(2:U^L()!\?34BJ0=!00_,
M7X^`]7?\N^'&3[D0W3K6*QMY9SZ@U!$OY9*CW:J?O7E?ZMX)-$K;9+J:.(>O
MQ,A^L1T/L.@=ZT8'VFSC<),-3L?Y4O%[H\82;DW6(QD6]CK$5***0Y'YY*+>
MQ[V/0?G5.WY(J`J%,<H@)?-TYN29WC&$LU_%,]K#8S-M`GV['8?%2C`@TI7P
MZ:'_`!K"<ER]VTG&8IWNX14M%4,H/P^(ZBM:>XZ[=?Z9=[2/:+O'>(M^A;-T
MSJ+?2V#)L@MZ92B8XD9Q]G=/%^"@/@1,PC^3K28^8]F)'"+=X+<3Z1"!]94#
M6[2<9[OQH7:/*$#U-(3]0))U&>Z=O4LB`KFEG?IQS&6))ED.(DYMW#9%60C'
MWT\[!'FK;&3[F"L*14E42F>LG/TJ_P!]$W`EZLE40X^F&,"*T9,3!0T56%5;
M:C*&7P/PL-P\"/'5</))_68_KT3N5DI*I;;)T-&%65MK>CJIH?$:L_>V!2=4
MZMI3A&=TXHRU&PYDBIQ]^:MY@PO+M*STLB5M/O<A3BBB[B>N#.39*,W2XJ&0
M(+8$VP$;$2(7F?W,O>477,KV#E\XGR]M*8B5Z1JHZJ(EZ;8RI#`4J:U:K$G3
M^X/:X"VXS:R<;B\G&S1AP#]LL11O,/7<X(VDUH*47X0!H%7>9S<QS%W4=D[1
M*I?C=3QYD>"Q.C&-G94"OJ_B!G%5>PQC9X8CE)L:3G8^3_2^0Y2'7$WE-\!=
M79["OA^U^.MHO@NI[=IR2*T:<M(C$=*T5DZ5'04KH?\`=/,)D>XEW-(/,MH)
MA%M!ITB`1@#U\65C6GIU-^Q]V#58QDSC8_1.1:,(]JW8L6B&P4:1%JS:)$0;
M-T2!B/@B2**92E#Y`'5)R?*S<RN9),XID8DDFU-23U)_\1Z3JU5^8B%%"KB&
M"@4`^\>C^@U*QVK.\BOW.\D93I,7K4]Q#!XJI41:9>VNLI-KNFZD[!.#$PE=
M3BV]%K(MU7K9D^<^N*Y@*5H)?(/GY+5W=#M`O;7'6M[+DA=S74S(J"$QT"KN
M9]WFO6A*BE/SO'IJQ>WW<IN>7=Q`EB;:&WC#%C+OJ6-%6GE)X@,:U/V:4U`5
M[I+$&8&^U^+LWRD%./L'3.#X#'U>MK9LZ<UVO6^#METE;#6Y1VF0[6%E)-O8
M&KMOZPI_6IB8$Q.*"@$O?Y8\OB&XK=82.1%S27KRNA(#M&T<:JX'BRC8RFE=
MI\:;A6GOF`Q>6&?M<P$9L7]V6-6`)59%=R5/J)W`BM-P-!7::;5U$]T";&6.
M\=XLV"U>":C*'4JQ2FUXPQ:F<:Z=1-8B6<&R>+8^M#1*-3>'8LB&4(VF44/4
MY]--,G!"XSEORSC)Y"XRF`R>R2>9Y#'<(6`9V+$>:AW4J32L9-/$D]=>_C??
M^*RLX<?F[`[88E3?"P!(4!1^B84!H/WZCU`#IJ37'V0>QKWJ<O-YVST=C<=D
M?U.;0#:EY=<Y!QK?WU2K9Y&4*R@F-?N+2H6E.'-+NEE0CG3QVFD)SJ`"1.2U
MKD,?WL[-X@V]M,8N.^<6,D`BFB#O1:L7C,B;MJ@;U52:`=3JP['(=K>YV06=
MXUFS*Q@!)3)')M6K``(X1B*DG:68#QZ#6QO<#9`B,`]J.YXXJ:+>"99$G,3X
M$JT4V5.`,JVVDFT^]C6GK**.%&R%.HB[8PB8P^F?@PCSXX[L)839[NE#D;HE
MWMTGN78^ER"@8TZ5\R4-[QTUZ.\-]'A>WLUK;4C$K10(!Z`#OVCV;(RONT>3
MVS>%U;UN7EW+:S<56.$-?+01DKZ8F\EKRB[1K$40A^0*FHI6XZ9#\H@(]('Y
MD<R+'B%IB0:27M^E?XD(WM_EF/5+=@,6;GD=SDS0QVUJP'L>0A5^M/,UJSV[
MK@6G=FI;8Z@HG=T'/C(4AYY6.E7G+PR`\`(?8^B$_P`@^QUD_F"7?VLF8=0)
M[8_Y:BOY=>/LDX3N$58T+0R@>T[2U/J!/T:^TW.M<]WF^]#7L'T)^]>XDKUS
M0P=69...9RTBL38VD7\MF;)38Y"@@0LVZ;2KEHL8`]9(&"0B(^4.O%PZUM^S
MW9V3-7RJ,K)";EU/0M/,`L$)]/P@QJP]!WGUZ]7)[B;N?W2CP]H6.+AE$((\
M!'&299/5U^-E/YPV+ZM:,[_%^KD]W#+)BRD(HL,?ZOXEQ/KU4(=IR6/@V-4K
M1;$^BF2?(@1*,?6HS4?GRV\?$.L[V(L;B#@$>4O3NO\`)W4]W(Q\6,C[0Q_C
M!`WTZP?>F\AGYF<;:#;:V-O%;HH\`%7=0#^"7*_1I8FD`-=$^Q)4\A210A96
MK:K7_/CU10HD66M>0XZQ9$KJ2@!P;ZI=S88]H3Y\@4.BMS7=SCOC+CT^.*3*
M16H]6R(I$Y]P".VD=Q0+Q/M1%=D;7CQ\EQU\=T@:51[ZLJCZ!H17;9W5A-"=
MJ(39ZT8O=YED:]4;K"P]=1MZ%-60L-T8I1#NQJS+FOV4%1;P[E\B*0-P,<SO
MS></*(&:/<;ALW.N+OQJVNA9I)+&S/Y?F`K&=P3:'3Q8*:UZ;?#1.X+RV'B/
M(CG9K8W3*CA1OV$%QMW;MC_FEA2G6OCTTC7_`/6?`_X&Y;_,)'?W1]'G_I5G
M_MM/U4_M&KM_ZBHO[);]8/\`L-(W[?&W<CO3JS1=FWN+'.'V>09&UIP52=VE
M.X+J0M:LDC64)L9E*`K:9TY9W$KG33!MP1,`'SFYZ///N)Q\(Y/-QM+H7;P+
M&6D">6-SH'V[=[_9#"IW>/HU>/#^0R<JP$.<>W-L)B]$+;S16*5KM3Q*GT:"
M73DAWX[]#5X1)2:KM]W??V-4H""Y%<78;LCB7(!C<"06AJ)CM-/D?L^4X!\^
MG%>'\"=C"A^"X@PH3U4FG0+]?FRUT2K7_P"W]Y0_C$^2+>NL4+%NOOA2GY-6
M177.K3;U6T^X'3KTIW6]@H^ELVPO5HC#\9.)1B28"^N[K&-6*[$Z:(`!Y%9%
MTT35'[YU2B)N3"/71?L*;B/M98/>,=FZ<KN]$8FDI]%0Q'LT(.\OW=^XUPMJ
MH,H$.\#TMY49^NE![].R_J<R!_#?^C?]3G[\M_Y`_P"+]^_V_O\`[O0@_KC'
M^S_WS[QZ/\U_@_)I??<+KU?_`!WE>/Y__;TZ-![KC,_U=PU,UY:+!Y(6!O69
MI]$BO(F6GGK.D505D@'@HHHPDP)!$.>%1^72/^5K#;;3*\@<=7DCMT/L0&1_
MKWQ_5J@/F)ROQ8_"H1T5YF'\8A$/T;'^O71/M4<.?@N`MFL\/&!2.<A94KV.
M(9^=,/5/#8UK7XQ($04'Q^G6F;Z)3@'@*C</]7K7OFCS'G9W&X-&^&WM7F8?
MPIGVBOM"Q?4=9OY>L6(,%>Y9EH\]PL8/K6-=W3V$RT]ZZ5UT6=(755GW1<C0
MF4>X;N9>ZZ5$()[GB\1D>JW3*FD\1ISHE.5D@*7P,:4<5X[@3?$XJ^8?$>NH
M?;+'S8OM_B+*XKYRV,;&OHWCS*?R=U/937/KN->1Y/G61F@Z(;ID'HKL.RO\
MJE?;6NK#S12M1^HG;%U\:W!06;/$>K</D"[&6`4C,%_U/<9*N"2@&#D@L7D@
MZ(/(?F=<_><7$G+.Y=^;3XGN\FT4?M'F"&/ZP%.FMQ6%./\`"+,77PK;V"R2
M>P[/,D^HEM"'[+N,:=N%W0VEOSU$56UTINUS+GW(4+?4HE[6)V7G5'3:+9S#
M">`\;*D_7"]-W((*D.!Q;>;C[(B#3[Q9.\XCVR-K@7EBO";>VB:+<'55H25*
M]5_1QL*BE*Z*7:^RM>3=PWO,RD4D"B:>19`I1F-5ZANA^-U:GLKIS'[&O;3_
M`,-6F7]F&'?Z)Z$OXQ[D_P!I9G^FN/YVEC^'N$?\%B_Z*#^;K=N(,2ZR88:V
MUUKWC+#-`&3:M'EM2P_5J;7G$RG#I/SQ)9DM39M3O1:_4N`;`OY@(*I_)QYC
M<X7+Y;DV9>%.07-Y/M)$?WAY'"[J;MN\FE:"M/4*ZRF.L<'CED.'@M80P!<0
MHBUI6F[8!6E32OK--0@:E>X&U^WEV'J>IESUO=XXALIFLT$G8<I7NFV*H/Y2
M)B9"3BZQ)5YU76S9Z]M+F.!HU045$#.E"$`#G$I375ROL)G^$X"7E5ED1<36
MNQML,4B2!2P5G5PY("`[B0/L@GH-5;QOO#@N6YE./36C0B?<*RLI4D*2%*E:
M$M3:!7[1`%==H[&=EWM:Y;A[#8[UKS1,1*(LW<C*Y`Q?+K88_`D$DSJNI=T6
M">1U'33;%Y4.H^CUD2\<G`0YZTWCW>/N=BIH[>QR$]W4@+%,OWC<?0HW`R]?
M"BN#ZM;/FNV7`\G$TEY90P4!)>(^3M];$*1'[:LI&A#:38<1D.[]A7%^K-QF
M,A4ZB[>(/J+DQHB"3R9P_C&Z.)J5O3XS`B;8L>\H,(N=94A4T'*:P`4H%6*3
MII\TS!C[2WF2Y/"EO=SXDB2$GHL\T6T1BO6HE8`#J01X]*Z*/$L2I[G6]AQR
M9YK.'(`I*/SH8I-Q8D=*&-2?0#X`=::F_P#==YC,>1U#U\9NC`5%KD/,UB9%
M4'RG,LI%4>F.%4@\/L`E/%(8?RFX^?5*_*SAZ1Y;/N/$Q6Z'W;I)!^6+5J_,
M5E"(\?AD(H=\S#ZDC/Y)!].ND?:YX:5JVGVQ6;GK0$7&7\LC6(EP<@`HZK6*
M*H5LDLF<2^;Z<;/<)5+@!X$Z`_DZUWYFLP+KEV.PJ&JVEKO8>IYW\/?LC0^X
MZSW8#%&UXO=9-UH]S<;0?6D2]#_C2./HT0C7O9*UZIYGR#E6B%43NCR@9SQM
M695)8R"U:E,HU^:I86ILH0Q3@^KK645=-N/@Y33$?`!Z6F?XY:\IQ%OC+[K9
MK/;S.M*AQ"ZR;#['*@-_!)T:<+R&;C67N,A;`_>C#-&A!H5:2-H]X]JABP]H
M&E5>V`T];4O&V7M\K\T*S<W8DEBK%;Z33`A66/JF]1D\DVU%PN4?^7GK5'(,
M`6*("4L&N`B)51Z+OS+\N:\R-IP6P)98=L\P'IE<%84IZU0EJ>GS%]6D/V#X
MR+3'7'+;P`2W!,<1/HC4@R,#ZF<!?10QL/`Z*]D^9FMS=XKM+1QE7TOLWM#*
M(0OI@*BAD<G9,-&0":)0\PB1K&2B!2@'@!"!\@Z4&-AAX=PF&*0!8<;C5W?Z
MF&KGZ2I.CWD)9.5<VD>,DO>WYVGU>;)\(^C<`-.!]PK?HK`':ED,1UI5*,1R
M3:\/X)KS!,Q$E2UBN.$KA(-T$B\#],G7L=BW4\H<`58"CX&Z%78&PES_`'2&
M6N07-O%/<N?X;_HP3[=TU1[M+#O+?1X;M[)90G9Y[Q0)[E_24]VV*A]AU'7[
M<+436B]:U9MS'L?C?"&0GEPRZVJ5&1RU`4JS.X>`H5<:J2KJ&;6IN[5C$)>>
MM"J:IDBD!<S$O(CY`XL+YB.6\EL>1V6(XY<WMND5H9)?(:1`S2N0H8H1NVJ@
M(KX;CZ]:1V.XY@I^/7.2S4%I+++<!4\Y8W(5%K5=X-*ER#3QV]?#2*_V->VG
M_AJTR_LPP[_1/1[_`!CW)_M+,_TUQ_.U=GX>X1_P6+_HH/YNOI-D;SCO4W17
M.E^QC&52G4?#N!\CS%$AZ.QBHFJQDA'UZ7&NQT"PA"(131)Q:%TDRD0*4/64
M'\X1Z\W'++(<JYQ8V.3:6:]N[Z%96E+,Y!==Y8M5C1`3U]`UZ,U>6N!XO=WM
MBL:6]M:2-&J`!00IVA0M`*O0=/2=#+]L;C5C8][+SEVR/F;9EAK!]@6:R$F[
M0;@I;\CS$766OE6=*I^=RM7DIDQA#D>!'GX^+#^93(R6_!X,3;JQDO+U`0H)
M_1Q*SGP]&_R]&'L'8"ZY9<Y62GEV]NU*^(>1@J]3ZT\SZM,JW"[@&L>D^)Y_
M)^7<DUCZME'.E:GCR&GXA]?\AS94C_00%3KR+I5^Z4>.0*19V9,&;%,15<*$
M3*(]#[B/`N2\SRL>,Q-M+L+#S)61A%$OI9WI04'@M=S'HH)TF^2\NP?%<>]_
ME)T!53MC##S)&]"HM:FI\3]E1U8@:$7VL-?<H=U/NAR^RV4X89&@U'*RFQV=
M9<[<RE;3F!F5IO'&*V*BH%2<A(2[!JV3:_?+!QJYS`'E*!FEW/S^,[7]LUXY
MBWVW\MK]TMEK\>W;MEF/\526+?Z1U]>BMV]Q&0[A=P'Y)D$)L8IS<2G\VNXM
M'$/6"PIM_P!&K>KK8E=<^M,_0=>_-K_AK(/<$G[-G#?7%.`I1QBC&C6EXVM6
M#-G;W+1U)9M95(LFK8\:8ULU0<EF+=^+*@F@Z,HB7@JI2G^+7[&9[,V'`H[;
M"8*ZOXA=3&29+FSC4R$CH$FG20;8_+%2M#X@TT5>\&'PE[RTS9O+PV<OW>/R
MXVAN7(C`/4M%#(AJ_F$4;TT(J#I#W9!J.$J)VZ\25?!.68+.%=C;!D;]9\FU
MRK7:EQ5COCJZ2SR?]"M9$@JY<(TL6W7:LR?5M$Q520*HF)DSD'H_]ZKO-7W<
M&ZN<Y:O97#1Q;(7>.0I$(U"U>)GC.XAF^%C0D@]0=71VNM\3:<,MH,-<+=6B
MM)64*Z;F+L3\,BHXH"%ZJ*@`CH=2V=51JPM5A>1]3M05\AY"7F^ZI@UC-KWN
MXK3#-]J_NHJY92ZMDDU))H]40PTLV5<-GQCD5,0YTS&*(E,)>!'I9CN5<N7'
MP+!Q>],`A3:1>8ZA7:*$5N0:$4IT!]F@ED^/<0;*3-<9^!9S*VX?=KRH->HZ
M6Y'U$^\Z>MNK5[19>UWFNIV+)U#QS-26L!XV_96AJM?)S'=>A`K,>&2+)`5&
MLL9_(+NNGJZ<@+%J@@Y>E243`Q3>4W08X;<VUMW.L[JVMI[B%<G6*!GB69FW
MGR4=W*1!]^S<256H-/1I><F@EFX/=07,\4)-C264+(45=@\UE50TFW9NVBC,
M.E0>NJ_8VI.E7E#S]UW`?D\.//JYNSY?W/O85X^'3T_%?-/[K7WZYCOVG0T7
MCG#-WP\A@W>RVO?V;7B_9)TD_P#J[K]_E<W6_N5Z^?Q7S7^ZU]^N8[]IU]_P
MYQ'^\,7ZM??LVE:^VTQ7K3BZI[7-<,;04'9NZ3%EQ@YN,G2L:9=QNG4JJUB+
M4E4XYPVR_3JA)RHR<LI+JF49$7;I^F0J@E.(`):^8O*<DR=UBVS.,GQMFD<P
MC$DT$N]R8]Y!MY)`NU?+'Q$$U-.FD/V3L,!86E\F(ODOKIGB\QA'-'M7])L%
M)HXR:G?X`CIU/4:@![A.N7:[GL[Y,N6H?<)Q_2RRUWL;J>PMD7".T[F!JER"
M;<DGV6.LET#"5O92M95GP6.P1^E6103$H-WJZ/I<7UP#D/<V#!VUGRW`7$VR
M%`MQ%<V09X]HVF6&6YC*OMIN.X$GQ1375-<WPG;VXS4]SQ[,Q07+2-NA>"[*
M*]3NV21P2`K7[(`H!X,137.RFN-HFX=BVV%[@:-%Q"'TP%E[MBWN2W&L`RY(
M"*D3"3NK\)6G7"0@*)%'K8AN``#%#@>M@'(;6&9FX_@#/ENOPQS8F-Z^G<RW
MK./;\)UC&P-_)"JY_-^5BNE"8<@X\?S%-H%/6GYPZZ51V)<;=IC&$W=8'4/8
MPFS6U*U/2=Y!OUQQ]?<8V)&CFD&A'<9C.HWZIUM./IJ<N5L:1^@7E'HK"W%\
MY\@MDRE[OAD>ZN3@AGY9CCC>+B:D44<L4R&2AH9I(G>LFVNS<$6F[8M=Q-]]
MI;+MS8M+#Q:\%]G/*'FR/')$VRHJ(TD1:)NH6VEC7;N:FT:CB[^^`<29#WW-
M9<Z[XXJU^=*X7QVSQ]CBU8-V9ODLUHS-Y9BKRZUBQAC>T5%89:[GF#`DFZ]=
M%,I`5(4>!-8G8C.Y?'\%%M@L'=7Z"\E,LJ7%G&IE(3X0DTT<GPQ^7U*T)K0Z
MTCO'B,+>\K6;.9:&RD^[((XS#<N?+JW4M%#(G63S/2#2E1ZT3]GBJ8=IG;7P
M-5<*Y2@<PTJ+B+\@_P`HUVL7"I1=GM:][M;FXOD:Q>X>!N,:5C-N%FQ4WK-%
M51)N0Y0$AB&$^]W+K,7G<>^NLU:O:7K/$1"[QNR((D$8WQ,\9JH!^%B`20>H
M.KK[;P8JVX39P8:=;FQ59*2JKH&8R.7.UU5Q1B1\2BH`(%"-`[F]2M+E9V:,
MOW6\%-15FY0RY`U;W557;>I(N!6(`$PR*"JR'(AX'$AC!X&X\>G)#RKF8@0+
MQ>^(V"G^^8[KT_YG]SZ-$.?CO"S<L9>06X;=U'W:]^G_`,O^[].GW52N8D7[
M5/ZI:B9#@&.(5=/;'7<3976@+4YC&L&;'4K&KY!E:M%Q1;NO,I.1<R+]@1B$
MJ:2!5(R'U'*?01N;C*KW2^]\LMY&RPRZ//`'0$MYJD1*[-Y6VFU%;=Y>RAW;
M>NF)!!CSP+[OQZ91CCC66&4JYHOE$>8R`>86\69=N_=4$;NFAT=K[6W2&G[^
M:G64_<8Q!EQ[#Y3B'-2QO7M?-K:G+V^]&CI%OC^.:V*^XI@ZE$BG<5F*XJ/G
M2"8@CY`-YS%Z77<OD7-;O@>4MAQZ[M8WM6#S-=63K'%4>:Q2*=Y&_1[A15)Z
MU\!HT\!PG#K7FME<)FH+FX6X^&(072EI.NP!G@1`1)M/5J=*:G)]R1B:DY2I
M^JI,L;54'6/'<+:LE'9+7/%^<,E&N5X?PM<*S1;EP[3;>2'"#K[5Z8HR!4!7
M^J/Z(F]-0`I/Y=<K>XR[RAQ6+GR61>.&OES6T7EQAGK7[Q)'NW,5^S6FT5\1
MJUN]V.L<A8V(RN0CL,>KR=6BFDWN0E/\S')3:`?M`5W=/`Z*,?4G2?G])W7<
M`^;C\_5S=?GC_>PKSQTI?Q7S3T<6OOUS'?M.CNO'.'4^#D,-/9;7W[-KQCJ3
MI+P/'==U]YX'CG5S=;CGY<_]E?ASU\_BOFG]UK[]<QW[3K[#CG$*]>0Q4_Y:
M^_9M+QSUB_$\Q[>VA8WQ/LU2JA@!EB;#+2U;%OL;9<EJS-5:)O$(K<I9MCZM
M5%]E)B%KR(@*1T7$45=HFNH+HI`*<P$W!9/*0]_)\CE,;-+G6NK@QV@F@#J[
M1-Y:F5Y!"=D/4$248@;:]!I+9BPQ\G:&.QM+Y(\2+:$/<^7*0P#KO81JC2C?
M+X@I4`MNIU.B,EU)TRX'R=UW!?'(<^GJYN]QSX\<^3"O^GI8?BOF7IXM??KF
M._:=&>/CG#NOE\A@^BVO?V;6TL3:B=KD;0U7SUW;*\2KMU$U'\5B74?:I2U2
MC,IBB=LWG[IBPC&#,H7D`6-&R`%^28]8O*\L[G?=BN#XI(;LCHT]]8A%/K*Q
MSDM[@Z>_63L..=NQ.&S/(B;4'JL=I=U/\IH0%/M*M[M/-[9S31&/U8JS'MY2
ME:G,$,Y&1:KS,4G-I6F5N2`I)SLCDM*VQT1=T[P\`J2BQ9=HV7!J9$$4B-/I
MR@&.Y#\XDY/*_/UD3.%00K;=BQG[(AV%H_+'4?`Q&[=N)?<=+OA2\57`QKP]
>HVQ`)%5K4MZ3)N`?>>GV@/AV[0$VZD#ZT+6VZ__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
